Sign In
CPSI Share                                                                      
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​​
Publication Type: Medication Safety Notice
Single or Multiple Incident: Multiple
Date: 4/1/2018 12:00:00 AM
Country: Australia

The purpose of this safety notice is to raise awareness of the availability of a new high concentration insulin product and provide information relevant to its safe use. Toujeo® (insulin glargine 300 units/mL) is a new high concentration insulin product, three times the concentration of standard insulin preparations (e.g. Lantus® 100 units/mL). It is only available in a pre-filled disposable pen device (Toujeo SoloStar®), and not in vials and must never be drawn up into a standard 100 unit/mL insulin syringe. The notice stresses that insulin syringes are calibrated for use with 100 units/mL insulin products. They cannot be used for higher concentration insulin products including Toujeo®. The notice provides recommended actions to prevent medication incidents with this new product.

Additional Details

pre-filled disposable pen device, Toujeo SoloStar®, Lantus SoloStar®
insulin, insulin glargine (Toujeo®, Lantus®)
Medication/IV List:
insulin, subcutaneous and IV

Insulin safety - High strength insulin glargine 300 units/mL